As with any medical procedure, to undergo genetic testing, informed consent must be given.According to the National Institutes of Health, informed consent (in the context of genetic testing) is the process of making sure that, wherever possible, a patient fully understands:
With this information, a patient can make an educated, voluntary choice i.e. they are informed to a level such that they can provide consent. This is usually a legal and ethical requirement in medicine.Whilst this might seem like a relatively simple concept, for genetic testing, informed consent suddenly becomes a whole lot more complex. Bioethicists, experts in the ethical practice of biology and medicine, often use case studies to explore these complexities and to discuss potential solutions to the dilemmas arising from them.
Jodie is a 28-year-old woman who is thinking about having children. However, she has a family history of limb-girdle muscular dystrophy and is considering undergoing genetic screening to determine if she is a carrier of any variants (a.k.a. mutations in her genome) associated with the disease.
Genetic Counselor Margarita Raygada, Ph.D., explains the role of a genetic counselor in cancer care and shares the benefits and implications of genetic testing for patients and their families.Genetic counselors are individuals educated in both medical genetics and counseling. This gives them the expertise to provide patients with the knowledge required to give consent, but also to offer guidance and support. As such, they are most likely the person who will be responsible for gaining informed consent from the patient.
Laura Hercher, Director of Research in Human Genetics at Sarah Lawrence College, has almost 20 years experience working as a genetic counselor. She emphasizes that the role of counseling goes far beyond testing alone:
Genetic counseling is about more than genetic testing. It can obviously be about that, and a genetic counselor would be a good person to discuss genetic testing with, but we meet with people where genetic testing isn't on the table at all.
I think that there is an element of education in many genetic counseling sessions or interpretation but also in many circumstances, theres what we call establishing a therapeutic relationship, where you do the counseling side of it.
Continuing on this theme, Hercher points out a key aspect of genetic counseling and something which is crucial to the consent process but often forgotten amongst the hype surrounding genetic testing.
We [genetic counselors] don't take for granted that somebody will want genetic testing. They have the right to say no these are shared norms in genetics in the UK and the US.
However, in Jodies case, she has expressed interest in genetic testing. How does a genetic counselor go about establishing informed consent for this?
You have to consider both of these two very basic things, Hercher begins. Make sure the person has an understanding of what genetic testing may tell them and also have an understanding of what genetic testing may not tell them.
These are very important to understand because, number one, you don't want someone to walk away from the experience saying, "Okay, great, I've been tested. I don't have a disease, if that isn't comprehensive.
Number two, we want to talk about what the test will show the patient, both in terms of setting up correct expectations that's consent but also by identifying additional things they might find out that are not necessarily the goals of testing.
The blood sample provided by Jodie undergoes whole exome sequencing. Upon sequence analysis, its found that Jodie does not have any of the variants currently associated with limb-girdle muscular dystrophy. However, the person analyzing the data also checks for other common disease-associated variants. They discover that Jodie has a mutation in BRCA2 that puts her at a higher risk of developing breast and/or ovarian cancer.
The discovery described above is known as a secondary finding, meaning that whilst its identification may not have been the main goal of the test, its presence was actively sought. This is different to an incidental finding, although the terms are often used interchangeably.The potential for secondary findings demonstrates how consent in genetic testing isnt as simple as a single yes or no answer. The decision to actively look for other variants and have them reported back provides an additional layer of consideration to the consent process.
In 2013, the American College of Medical Genetics and Genomics (AMCG) published recommendations for the responsible handling of incidental findings emerging from clinical exome or genome sequencing. This includes clinicians being responsible for alerting patients to the possibility that sequencing could result in incidental findings, and that these may warrant further investigation.1A proper informed consent for genetic testing would give the person a notion of what they might encounter as a part of testing, and what choices they have, about what [testing or results] they can get and what not to get, if there are choices available in the setting in which you're operating.
Jodie doesnt just have a decision to make about whether or not she wants the test, she also has to consider what results she would want reported back to her. The availability of choice is an important one because of the potential implications, both physically and mentally, of being given information you werent expecting or didnt want to receive.
Jodies results show that she, and potentially her first-degree relatives, are at a high risk of developing breast and/or ovarian cancer. Although it isnt a guarantee that she would develop those diseases, this knowledge could impact upon decisions she makes about her healthcare. For people carrying a disease-associated BRCA mutation, preventative, albeit drastic, surgical measures may be available, including mastectomies and oophorectomies.
Preventative surgery, or even just knowing that you may develop a disease can also take an emotional toll. In addition, a patient could find out that they have variation that means they will develop a condition at some point in their lifetime, such as Huntingtons disease. This may have an impact on mental health if there are currently very limited or no treatment options for the condition diagnosed, although further and continual research needs to be conducted to assess the extent of such an impact.
Secondary findings can also emerge with advances in research; a variant that may not have been considered a pathogenic variant before could be considered so in the future, or vice versa. Patients like Jodie would need to think about whether they would want to be re-contacted with new or updated information.
Thats a lot of factors for someone to consider before consenting. How can we simplify consent to account for all of those decisions and outcomes, if its even possible?
This requires time something which the healthcare system doesnt always have enough of. How do we create a process that works for both clinicians and patients?
The answers people are coming up with tend to be that we need better tools, Hercher tells me. And that includes online or digital tools that would allow people to interact with the information. You know, if you sit somebody down and spout off 15 minutes worth of information, dense information, you're not doing anything for them.
So, what's needed to improve the situation is new tools that allow people to tackle it over time, at their own pace, exploring what they want to and when. That would optimize the situation for both the caregiver and the patient. And allow them to go back to it [the information] to refresh their memory and so on. The optimal consent process is not "let's decide everything we can fit into this space of time consent, optimally, is an ongoing process.
Research conducted in the UK seems to agree. A recent report from the Joint Committee on Genomics in Medicine sums it up nicely:Consent may be more appropriately seen as an ongoing conversation that needs updating and clarifying where necessary, rather than as a single historical event that needs to be revisited.Reference
Go here to read the rest:
Exploring the Ethics of Genetic Testing: What Does Consent Mean? - Technology Networks
- Department of Genetic Medicine - January 6th, 2025
- Research Services | Johns Hopkins Institute of Genetic Medicine - January 6th, 2025
- Patient Care | Johns Hopkins Department of Genetic Medicine - January 6th, 2025
- Specialty Clinics | Johns Hopkins Institute of Genetic Medicine - January 6th, 2025
- Pediatric Genetic Medicine at Johns Hopkins Children's Center - January 6th, 2025
- Research Centers | Johns Hopkins Institute of Genetic Medicine - January 6th, 2025
- About Us - Johns Hopkins Medicine - January 6th, 2025
- Graduate Programs & Training | Johns Hopkins Medicine - January 6th, 2025
- Request an Appointment | Johns Hopkins Institute of Genetic Medicine - January 6th, 2025
- Clemson professor Trudy Mackay elected to the National Academy of Medicine - Clemson News - October 22nd, 2024
- Research sheds new light on the behavior of KRAS gene in pancreatic and colorectal cancer - News-Medical.Net - October 22nd, 2024
- Pushing the boundaries of rare disease diagnostics with the help of the first Undiagnosed Hackathon - Nature.com - October 22nd, 2024
- Tailored Genetic Medicine: AAV Gene Therapy and mRNA Vaccines Redefine Healthcare's Future - Intelligent Living - October 22nd, 2024
- The Genetic Link to Parkinson's Disease - Hopkins Medicine - August 27th, 2022
- Epic Bio makes gene therapies by editing the epigenome - Labiotech.eu - August 27th, 2022
- Ovid turns to gene therapy startup to restock drug pipeline - BioPharma Dive - August 27th, 2022
- Whole-exome analysis of 177 pediatric patients with undiagnosed diseases | Scientific Reports - Nature.com - August 27th, 2022
- First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN (valoctocogene roxaparvovec), Approved by European Commission (EC) -... - August 27th, 2022
- Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases - BioSpace - August 27th, 2022
- ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines - Business Wire - August 27th, 2022
- ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene... - August 27th, 2022
- Genetic variants cause different reactions to psychedelic therapy - The Well : The Well - The Well - August 27th, 2022
- Personalized Medicine for Prostate Cancer: What It Is and How It Works - Healthline - August 27th, 2022
- Four radical new fertility treatments just a few years away from clinics - The Guardian - August 27th, 2022
- Why are Rats Used in Medical Research? - MedicalResearch.com - August 27th, 2022
- The Columns Stepping Stones in STEM Washington and Lee University - The Columns - August 27th, 2022
- Study points to new approach to clearing toxic waste from brain Washington University School of Medicine in St. Louis - Washington University School... - August 27th, 2022
- ALS Gene Therapy SynCav1 Found to Extend Survival in Mouse Model |... - ALS News Today - August 27th, 2022
- A New Kind of Chemo | The UCSB Current - The UCSB Current - August 27th, 2022
- Unraveling the mystery of who gets lung cancer and why - Genetic Literacy Project - June 16th, 2022
- How diet and the microbiome affect colorectal cancer - EurekAlert - June 16th, 2022
- Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear... - May 20th, 2022
- Money on the Move: SwanBio, Remix, Locus, Mirvie and More - BioSpace - May 20th, 2022
- DiNAQOR Opens DiNAMIQS Subsidiary to Partner with Gene Therapy Companies Bringing New Treatments to Patients - PR Newswire - May 20th, 2022
- Brain tumor growth may be halted with breast cancer drug - Medical News Today - May 20th, 2022
- LogicBio Therapeutics to Present at HC Wainwright Global Investment Conference - PR Newswire - May 20th, 2022
- Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, Presented at American Society of Gene... - May 20th, 2022
- Encoded Therapeutics Presents Nonclinical Data Showing Genomic Medicine Platform Yields Selective Expression to Optimize Gene Therapy Performance at... - May 20th, 2022
- California, Other States to Cover Rapid WGS of Newborns Under Medicaid, but Questions of Access Loom - GenomeWeb - May 20th, 2022
- Researchers Identify Role of 'Sonic the Hedgehog' Gene in Bone Repair - BioSpace - May 20th, 2022
- Targeting the Uneven Burden of Kidney Disease on Black Americans - The New York Times - May 20th, 2022
- ASC Therapeutics, U Mass Medical School, and the Clinic for Special Children Announce Podium Presentation of Safety and Efficacy in Murine and Bovine... - May 20th, 2022
- UC Davis Looks to Expand Genetic Breast Cancer Risk Education, Outreach for Hispanic Women - Precision Oncology News - May 20th, 2022
- Fly Researchers Find Another Layer to the Code of Life - Duke Today - May 20th, 2022
- CANbridge-UMass Chan Medical School Gene Therapy Research Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Business... - May 20th, 2022
- Omicron BA.4 and BA.5: What to know about the new variants - Medical News Today - May 20th, 2022
- Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting -... - May 20th, 2022
- FDA approves Lilly's Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2... - May 20th, 2022
- Elucidating the developmental origin of life-sustaining adrenal glands | Penn Today - Penn Today - May 20th, 2022
- 5 questions facing gene therapy in 2022 - BioPharma Dive - January 17th, 2022
- In a First, Man Receives a Heart From a Genetically Altered Pig - The New York Times - January 17th, 2022
- Antibodies, Easy Single-Cell, Genomics for All: Notes from the JP Morgan Healthcare Conference - Bio-IT World - January 17th, 2022
- Using genetics to conserve wildlife - Pursuit - January 17th, 2022
- Genetics of sudden unexplained death in children - National Institutes of Health - January 17th, 2022
- Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance - Yahoo Finance - January 17th, 2022
- Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically... - January 17th, 2022
- How The mRNA Vaccines Were Made: Halting Progress and Happy Accidents - The New York Times - January 17th, 2022
- Press Registration Is Now Open for the 2022 ACMG Annual Clinical Genetics Meeting - PRNewswire - January 17th, 2022
- A Novel Mutation in the TRPM4 Gene | RRCC - Dove Medical Press - January 17th, 2022
- Biomarkers and Candidate Therapeutic Drugs in Heart Failure | IJGM - Dove Medical Press - January 17th, 2022
- Genetic counseling program helps patients take control of their health - Medical University of South Carolina - June 24th, 2021
- One-year-old baby in UAE receives imported genetic medicine to treat rare disease - Gulf News - June 24th, 2021
- Black and non-Hispanic White Women Found to Have No Differences in Genetic Risk for Breast Cancer - Cancer Network - June 24th, 2021
- What's in your genes | The Crusader Newspaper Group - The Chicago Cusader - June 24th, 2021
- Immusoft Announces Formation of Scientific Advisory Board - Business Wire - June 24th, 2021
- Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress - Business... - June 24th, 2021
- Pacific Biosciences and Rady Children's Institute for Genomic Medicine Announce its First Research Collaboration for Whole - GlobeNewswire - June 24th, 2021
- Despite the challenges of COVID-19, Yale-PCCSM section members continued their work on scientific papers - Yale School of Medicine - June 24th, 2021
- Veritas Intercontinental: Genetics makes it possible to identify cardiovascular genetic risk and prevent cardiac accidents such as those that have... - June 24th, 2021
- New Research Uncovers How Cancers with Common Gene Mutation Develop Resistance to Targeted Drugs - Newswise - June 24th, 2021
- Celebrate the Third Annual Medical Genetics Awareness Week April 13-16, 2021 - PRNewswire - February 14th, 2021
- How will WNY fare in the race between vaccines and coronavirus variants? - Buffalo News - February 14th, 2021
- Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences - GlobeNewswire - February 14th, 2021
- ASCO GU 2021: The Landscape of Genetic Alterations Using ctDNA-based Comprehensive Genomic Profiling in Pat... - UroToday - February 14th, 2021
- The Human Genome and the Making of a Skeptical Biologist - Scientific American - February 14th, 2021
- Breast Cancer Gene Mutations Found in 30% of All Women - Medscape - February 1st, 2021
- Mysterious untreatable fevers once devastated whole families. This doctor discovered what caused them - CNN - February 1st, 2021
- CCMB team identifies variants of genes that metabolise drugs - BusinessLine - February 1st, 2021
- NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics - GlobeNewswire - February 1st, 2021
- Copy number variations linked to autism have diverse but overlapping effects - Spectrum - February 1st, 2021